vs

Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and NORTHRIM BANCORP INC (NRIM). Click either name above to swap in a different company.

Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $61.2M, roughly 1.0× NORTHRIM BANCORP INC). On growth, NORTHRIM BANCORP INC posted the faster year-over-year revenue change (11.6% vs 8.1%). NORTHRIM BANCORP INC produced more free cash flow last quarter ($133.9M vs $-1.8M). Over the past eight quarters, NORTHRIM BANCORP INC's revenue compounded faster (18.4% CAGR vs 17.7%).

Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.

Northrim Bancorp Inc is a U.S. regional bank holding company based in Anchorage, Alaska. It offers commercial and consumer banking services including deposit accounts, business and personal loans, mortgage products, and wealth management solutions, serving local small businesses, individual customers and corporate clients in its operating areas.

CTKB vs NRIM — Head-to-Head

Bigger by revenue
CTKB
CTKB
1.0× larger
CTKB
$62.1M
$61.2M
NRIM
Growing faster (revenue YoY)
NRIM
NRIM
+3.5% gap
NRIM
11.6%
8.1%
CTKB
More free cash flow
NRIM
NRIM
$135.6M more FCF
NRIM
$133.9M
$-1.8M
CTKB
Faster 2-yr revenue CAGR
NRIM
NRIM
Annualised
NRIM
18.4%
17.7%
CTKB

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CTKB
CTKB
NRIM
NRIM
Revenue
$62.1M
$61.2M
Net Profit
$-44.1M
Gross Margin
52.9%
79.9%
Operating Margin
-9.0%
27.2%
Net Margin
-70.9%
Revenue YoY
8.1%
11.6%
Net Profit YoY
-557.1%
EPS (diluted)
$-2.80

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTKB
CTKB
NRIM
NRIM
Q4 25
$62.1M
$61.2M
Q3 25
$52.3M
$77.2M
Q2 25
$45.6M
$61.4M
Q1 25
$41.5M
$55.8M
Q4 24
$57.5M
$54.8M
Q3 24
$51.5M
$51.0M
Q2 24
$46.6M
$46.5M
Q1 24
$44.9M
$43.7M
Net Profit
CTKB
CTKB
NRIM
NRIM
Q4 25
$-44.1M
Q3 25
$-5.5M
$27.1M
Q2 25
$-5.6M
$11.8M
Q1 25
$-11.4M
$13.3M
Q4 24
$9.6M
Q3 24
$941.0K
$8.8M
Q2 24
$-10.4M
$9.0M
Q1 24
$-6.2M
$8.2M
Gross Margin
CTKB
CTKB
NRIM
NRIM
Q4 25
52.9%
79.9%
Q3 25
52.7%
84.0%
Q2 25
52.3%
78.5%
Q1 25
48.6%
84.1%
Q4 24
58.5%
77.8%
Q3 24
56.3%
75.2%
Q2 24
54.6%
79.1%
Q1 24
51.3%
78.2%
Operating Margin
CTKB
CTKB
NRIM
NRIM
Q4 25
-9.0%
27.2%
Q3 25
-17.6%
44.8%
Q2 25
-23.3%
25.7%
Q1 25
-36.1%
31.5%
Q4 24
5.2%
24.3%
Q3 24
-8.2%
22.8%
Q2 24
-18.3%
24.9%
Q1 24
-23.9%
24.1%
Net Margin
CTKB
CTKB
NRIM
NRIM
Q4 25
-70.9%
Q3 25
-10.5%
35.1%
Q2 25
-12.2%
19.2%
Q1 25
-27.5%
23.9%
Q4 24
16.8%
Q3 24
1.8%
17.3%
Q2 24
-22.4%
19.4%
Q1 24
-13.8%
18.8%
EPS (diluted)
CTKB
CTKB
NRIM
NRIM
Q4 25
$-2.80
Q3 25
$1.20
Q2 25
$2.09
Q1 25
$2.38
Q4 24
$-1.83
Q3 24
$0.39
Q2 24
$1.62
Q1 24
$1.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTKB
CTKB
NRIM
NRIM
Cash + ST InvestmentsLiquidity on hand
$90.9M
Total DebtLower is stronger
$12.8M
Stockholders' EquityBook value
$341.7M
$326.5M
Total Assets
$461.5M
$3.3B
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTKB
CTKB
NRIM
NRIM
Q4 25
$90.9M
Q3 25
$93.3M
Q2 25
$75.5M
Q1 25
$95.3M
Q4 24
$98.7M
Q3 24
$162.3M
Q2 24
$177.9M
Q1 24
$168.8M
Total Debt
CTKB
CTKB
NRIM
NRIM
Q4 25
$12.8M
Q3 25
Q2 25
Q1 25
Q4 24
$23.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
CTKB
CTKB
NRIM
NRIM
Q4 25
$341.7M
$326.5M
Q3 25
$378.6M
$315.7M
Q2 25
$377.6M
$290.2M
Q1 25
$379.6M
$279.8M
Q4 24
$395.7M
$267.1M
Q3 24
$385.5M
$260.1M
Q2 24
$389.1M
$247.2M
Q1 24
$392.6M
$239.3M
Total Assets
CTKB
CTKB
NRIM
NRIM
Q4 25
$461.5M
$3.3B
Q3 25
$494.9M
$3.3B
Q2 25
$493.3M
$3.2B
Q1 25
$482.6M
$3.1B
Q4 24
$499.5M
$3.0B
Q3 24
$491.2M
$3.0B
Q2 24
$483.7M
$2.8B
Q1 24
$492.1M
$2.8B
Debt / Equity
CTKB
CTKB
NRIM
NRIM
Q4 25
0.04×
Q3 25
Q2 25
Q1 25
Q4 24
0.09×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTKB
CTKB
NRIM
NRIM
Operating Cash FlowLast quarter
$-771.0K
$139.3M
Free Cash FlowOCF − Capex
$-1.8M
$133.9M
FCF MarginFCF / Revenue
-2.9%
218.9%
Capex IntensityCapex / Revenue
1.6%
8.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-8.8M
$235.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTKB
CTKB
NRIM
NRIM
Q4 25
$-771.0K
$139.3M
Q3 25
$-3.9M
$92.7M
Q2 25
$108.0K
$-4.4M
Q1 25
$-125.0K
$16.5M
Q4 24
$2.0M
$-8.7M
Q3 24
$13.2M
$-201.0K
Q2 24
$6.2M
$-38.5M
Q1 24
$4.0M
$-5.5M
Free Cash Flow
CTKB
CTKB
NRIM
NRIM
Q4 25
$-1.8M
$133.9M
Q3 25
$-4.6M
$89.9M
Q2 25
$-1.5M
$-4.7M
Q1 25
$-974.0K
$16.3M
Q4 24
$1.1M
$-9.3M
Q3 24
$12.2M
$-330.0K
Q2 24
$5.2M
$-39.4M
Q1 24
$3.4M
$-6.6M
FCF Margin
CTKB
CTKB
NRIM
NRIM
Q4 25
-2.9%
218.9%
Q3 25
-8.7%
116.5%
Q2 25
-3.2%
-7.7%
Q1 25
-2.3%
29.3%
Q4 24
1.9%
-17.1%
Q3 24
23.7%
-0.6%
Q2 24
11.0%
-84.7%
Q1 24
7.6%
-15.1%
Capex Intensity
CTKB
CTKB
NRIM
NRIM
Q4 25
1.6%
8.9%
Q3 25
1.3%
3.5%
Q2 25
3.5%
0.5%
Q1 25
2.0%
0.4%
Q4 24
1.6%
1.1%
Q3 24
2.0%
0.3%
Q2 24
2.3%
1.9%
Q1 24
1.3%
2.4%
Cash Conversion
CTKB
CTKB
NRIM
NRIM
Q4 25
Q3 25
3.42×
Q2 25
-0.37×
Q1 25
1.24×
Q4 24
0.21×
Q3 24
14.05×
-0.02×
Q2 24
-4.27×
Q1 24
-0.68×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CTKB
CTKB

Products$46.6M75%
Services$15.5M25%

NRIM
NRIM

Community Banking Segment$44.3M72%
Specialty Finance Segment$7.4M12%
Other$4.7M8%
Home Mortgage Lending Segment$3.6M6%
Credit And Debit Card$1.2M2%

Related Comparisons